Norovirus Treatment Global Market Report 2025

The norovirus treatment market size has grown rapidly in recent years. It will grow from $1.75 billion in 2024 to $1.94 billion in 2025 at a compound annual growth rate (CAGR) of 11%. Growth during the historical period was driven by increasing global outbreaks of norovirus, heightened public awareness, a stronger emphasis on supportive care strategies, rising investments in vaccine development, improvements in healthcare infrastructure, and increased demand for efficient infection control practices.

The norovirus treatment market size is expected to see rapid growth in the next few years. It will grow to $2.91 billion in 2029 at a compound annual growth rate (CAGR) of 10.7%. Key factors contributing to this growth include increased funding for antiviral drug research, higher uptake of rapid diagnostic solutions, greater recognition of norovirus as a public health concern, expanded healthcare access in developing regions, and advancements in supportive care options aimed at reducing symptom severity. Prominent trends anticipated during the forecast period are progress in vaccine innovation, development of new antiviral treatments, enhancements in molecular diagnostics, utilization of AI-powered diagnostic systems, stronger public health initiatives, and the introduction of affordable point-of-care therapeutic options.

The rising incidence of infectious diseases is expected to drive the growth of the norovirus treatment market. These diseases, caused by bacteria, viruses, fungi, or parasites, include influenza, tuberculosis, HIV/AIDS, malaria, and norovirus, and can spread rapidly among people. Urban overcrowding plays a significant role in this trend by enabling faster transmission of pathogens within densely populated areas. Norovirus treatment helps mitigate the impact of such diseases by effectively managing symptoms and reducing spread through practices like proper hydration, hygiene, and isolation. For example, in March 2025, the World Health Organization reported that 10.8 million people globally were infected with tuberculosis in 2023, including 6 million men, 3.6 million women, and 1.3 million children. This growing burden of infectious diseases is contributing to the expansion of the norovirus treatment market.

Companies in the norovirus treatment market are increasingly focusing on innovative solutions such as advanced mRNA vaccines to promote targeted immunization, improve protection against severe infections, and reduce the global impact of norovirus-related illnesses. These mRNA vaccines use engineered messenger RNA to direct cells to produce specific proteins, eliciting a targeted immune response with enhanced stability, effectiveness, and adaptability against various pathogens. For instance, in October 2024, Moderna Inc., a US-based biotechnology company, in collaboration with the UK Health Security Agency (UKHSA), initiated the world’s first Phase 3 clinical trial of an mRNA norovirus vaccine (mRNA-1403) in the UK. This vaccine is designed to combat the highly contagious norovirus by prompting the body to generate viral proteins that stimulate a robust immune response, without using the live virus. Key features include the use of stabilized mRNA for improved durability, the capacity for rapid development in response to evolving viral strains, and the ability to trigger both antibody and T-cell responses.

In March 2024, Kenvue Inc., a US-based consumer healthcare company, partnered with the Association of Physicians of India (API) to support public health awareness and preventive care efforts. Through this collaboration, Kenvue seeks to improve clinical guidance on hydration and energy management for hospitalized patients with non-diarrheal illnesses. The partnership aims to promote evidence-based recommendations developed jointly with API, a professional organization representing internal medicine physicians in India.

Major players in the norovirus treatment market are Pfizer Inc., Johnson and Johnson, F. Hoffmann-La Roche Ltd., Merck and Co. Inc., AbbVie Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, Abbott Laboratories, Novartis AG, AstraZeneca plc, GSK plc, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Reckitt Benckiser Group plc, Sun Pharmaceutical Industries Ltd., Lupin Ltd., Aurobindo Pharma Limited, Cipla Inc., and Endo International plc.

North America was the largest region in the norovirus treatment market in 2024. The regions covered in norovirus treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the norovirus treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Norovirus treatment involves supportive care designed to alleviate symptoms like vomiting, diarrhea, and stomach pain caused by the virus. This care primarily focuses on maintaining hydration, getting adequate rest, and managing symptoms, as there is currently no specific antiviral medication available for norovirus.

Key components of norovirus treatment include electrolytes, intravenous fluids, antipyretics, analgesics, anti-diarrheal medications, and others. Electrolytes are essential minerals that carry an electric charge and play a crucial role in vital bodily functions such as nerve communication, muscle contractions, maintaining hydration, and regulating pH balance. Diagnostic approaches consist of stool tests, bacterial culture tests, and more. Routes of administration vary and include oral, intravenous, or subcutaneous methods, and these treatments are delivered across settings such as hospitals, clinics, and homecare environments.

The norovirus treatment market research report is one of a series of new reports that provides norovirus treatment market statistics, including the norovirus treatment industry global market size, regional shares, competitors with the norovirus treatment market share, detailed norovirus treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the norovirus treatment industry. This norovirus treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The norovirus treatment market includes revenues earned by entities by providing services such as symptom management, rehydration therapy, and stool tests. The market value includes the value of related goods sold by the service provider or included within the service offering. The norovirus treatment market also includes sales of oral rehydration solutions (ORS), anti-nausea medications, thermometers, disinfectants, and cleaning products. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.